Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Moodys
Medtronic
Harvard Business School
Boehringer Ingelheim

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,394,407

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,394,407 protect, and when does it expire?

Patent 8,394,407 protects RAYOS and is included in one NDA.

This patent has twenty-two patent family members in eighteen countries.

Summary for Patent: 8,394,407
Title:Delayed release tablet with defined core geometry
Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
Inventor(s): Vergnault; Guy (Kembs, FR), Grenier; Pascal (Kappelen, FR), Dragan; Christophe (Geispitzen, FR)
Assignee: Jagotec AG (Muttenz, CH)
Application Number:13/428,548
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,394,407
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Formulation; Device; Use;

Drugs Protected by US Patent 8,394,407

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Horizon Pharma Usa RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 AB RX Yes No   Request a Trial   Request a Trial Y TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET   Request a Trial
Horizon Pharma Usa RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 AB RX Yes No   Request a Trial   Request a Trial Y TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET   Request a Trial
Horizon Pharma Usa RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-003 Jul 26, 2012 AB RX Yes Yes   Request a Trial   Request a Trial Y TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET   Request a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,394,407

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0309342.4Apr 24, 2003

International Family Members for US Patent 8,394,407

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 512659   Request a Trial
Australia 2004231362   Request a Trial
Brazil PI0409652   Request a Trial
Canada 2523158   Request a Trial
China 102525993   Request a Trial
China 1777412   Request a Trial
Cyprus 1111835   Request a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Moodys
Boehringer Ingelheim
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.